CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: Further studies are therefore required to explore the mechanisms involved in the increase of CD8+ TCR-Vβ+ subpopulation that could have cytotoxic activity against CML cells in patients treated with dasatinib (Rossi et al., 2007).